공시 • Apr 10
Nanomix Corporation Common Stock Deleted from OTC Equity Nanomix Corporation Common Stock has been deleted from OTC Equity effective April 09, 2025, due to 12(j)Registration Revoked by SEC. 공시 • Nov 27
Nanomix Corporation Announces Chief Executive Officer Changes On November 3, 2023 (the “Effective Date”), Nanomix Corporation appointed David Ludvigson as interim chief executive officer of the Company, effective immediately. Mr. Ludvigson succeeds Dr. Thomas Schlumpberger who unexpectedly passed away on November 2, 2023. Mr. Ludvigson served as chief executive officer of the Company from June 2021 to July 2022, chief financial officer from June 2021 until January 2023 and as a director since June 2021. From June 2013 to June 2021, he served as CEO of Nanomix Inc. From October 2009 through present day, Mr. Ludvigson has served as President of Knight Ludvigson Advisors providing advisory and business consulting services to Life Science and Technology companies including M&A, financing, business strategy, go to market planning and sales channel strategy and implementation. Mr. Ludvigson serves on the board of directors of Imagion Biosystems Inc., One BioMed PTE LTD (privately held), Incando Therapeutics Inc. (privately held) and China Stem Cells Ltd. (privately held). Mr. Ludvigson received his BS and MAS in Accounting from Gies College of Business – University of Illinois Urbana-Champaign. 공시 • May 16
Nanomix Corporation announced delayed 10-Q filing On 05/15/2023, Nanomix Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Jan 26
Nanomix Corporation Appoints Christopher R. Hetterly as Chief Financial Officer Nanomix Corporation announced the appointment of Christopher R. Hetterly as Chief Financial Officer (CFO). Mr. Hetterly is a financial executive and entrepreneur, with over 25 years of financial leadership and banking experience. Previously, Mr. Hetterly was the CFO of Octagos Health, a healthcare Software-as-a-Service (SaaS) company. Prior to that, he was a CFO at Madrona Ventures portfolio companies. Mr. Hetterly was the Head of Technology Finance at GE Capital, Wells Fargo, and East West Bank, in addition to being CFO/CIO at Palo Alto Capital. He has raised capital from seed stage to IPO and beyond, and has experience in debt and equity financing, corporate development, business development, with particular expertise in building finance teams and leading in high growth environments. Mr. Hetterly has raised over $10 billion in capital in his career for well-known names such as eBay, Netflix and Symantec amongst others, and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources. He graduated from Brown University with a BA from the Honors Program. 공시 • Jun 23
Nanomix Corporation Initiates New Clinical Study for the eLab S1 Panel Nanomix Corporation announced that it has initiated a clinical validation study with Hospital Clinico San Carlos (HCSC) in Madrid, Spain to evaluate the performance of the Nanomix eLab® mobile immunoassay diagnostic system and the S1 Panel assay for the detection of critical infections such as sepsis in the emergency department. The principal investigator of the study is Dr. Juan González del Castillo, Internal Medicine Specialist, Assistant Physician of the Emergency Service of HCSC and Coordinator of the Infections Group of the Spanish Society of Emergency Medicine (SEMES). The Nanomix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanomix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration. 공시 • Jun 15
Nanomix Corporation Receives IVDR Certification for the eLab Analyzer Nanomix Corporation announced that it has received the EU Quality Management System Certificate under the new In Vitro Diagnostic Medical Devices Regulation (IVDR) for its eLab analyzer, part of the Nanomix eLab® system. The European Union (EU) IVDR replaces the legacy In Vitro Diagnostic Directive (IVDD) and was created to ensure a greater level of patient protection and regulation around the creation of in vitro diagnostic devices (IVDs). The Nanomix eLab® system is a rapid, easy-to-use, quantitative detection platform that performs a range of in vitro diagnostic assays. The platform consists of a hand-held analyzer and a disposable cartridge. The eLab System utilizes a proprietary nano-biosensor with multiple detection electrodes to generate multiple electrochemical assay results from a single patient sample. The Nanomix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. The Nanomix eLab® system has received the CE marking in Europe. 공시 • May 27
Nanomix Granted Ce Mark for Elab S1 Assay Panel for Whole Blood Samples Nanomix Corporation announced that it has received European CE mark designation for its eLab S1 assay panel for use with a lithium heparinized whole blood sample. The eLab S1 is currently marketed and CE marked for use with a plasma sample. The new authorization for a whole blood sample provides even faster results than the Company's earlier plasma-based panel by eliminating the step of first centrifuging blood to produce a plasma sample. Key Advantages: The ab b S1 assay panel is the first of its kind offering Procalcitonin(PCT), C-Reactive Protn (CRP) and LaLactate (LAC) for use on its testing device in emergency departments and decentralized healthcare environments,Faster time to results -- driving information within the initial clinical decision-making window,Increased accessibility and broader end-user market,Designed to help providers achieve better patient outcomes . The S1 Assay panel was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for LAC, CRP and PCT from a single plasma sample or venous whole blood sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The Nanomix eLab(R) system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanomix eLab(R) offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. About Nanomix CorporationNanomix (OTCQB: NNMX) is developing mobile point-of-care diagnostics with its Nan mix eLab(R) System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company's products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix's first assays address the need for faster diagnosis of critical infections as well as the rapid identification of current and prior SARS-CoV-2 infection. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. 공시 • May 18
Nanomix Corporation announced delayed 10-Q filing On 05/17/2022, Nanomix Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Mar 31
Nanomix Corporation Appoints Vidur Sahney as Chief Operating Officer Nanomix Corporation announced the appointment of Vidur Sahney as Chief Operating Officer. Mr. Sahney brings to Nanomix more than 20 years of experience in operations, quality, validation, manufacturing and research. In this newly created executive management position, Mr. Sahney will manage and be responsible for Nanomix operations including manufacturing, assay development and quality. Most recently, Mr. Sahney served as Chief Operating Officer of ExThera Medical where he led the initiative to secure U.S. Food and Drug Administration (FDA) Emergency Use Authorization site clearance and CE mark for a Class III /PMA medical device, and commercialized the novel hemoperfusion filter used to treat blood stream infections and COVID-19 in Europe and the U.S. 공시 • Mar 30
Nanomix Corporation announced delayed annual 10-K filing On 03/29/2022, Nanomix Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Dec 09
Nanomix Announces UK MHRA Registration for New Point of Care System Nanomix Corporation announced confirmation of registration from the Medicines & Healthcare products Regulatory Agency (MHRA) of the United Kingdom for the Nanomix eLab system and the S1 Panel Cartridge. The Nanomix eLab analyzer with S1 Panel Cartridge provides multiple host-response biomarker results that can assist healthcare providers in diagnosing and treating patients with critical infections, including sepsis. 공시 • Dec 02
Nanomix Corporation Submits Emergency Use Authorization Application for its Rapid Point-of-Care Antigen Panel to Detect COVID-19 Nanomix Corporation announced the Company has resubmitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for its eLab COVID-19 rapid antigen test. The application includes additional analytical and clinical development documentation in response to FDA review comments. The COVID-19 Antigen test cartridge is used with the Nanomix eLab Analyzer to provide electronically available results in 15 minutes. The Nanomix COVID-19 Rapid Antigen Test provides qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal (anterior nares) swabs. Nasal swab samples are collected using a provided swab and sample collection tube and then transferred to the single-use, microfluidic cartridge. The cartridge is run on the Nanomix eLab Analyzer which displays results in 15 minutes with the ability to print or send results electronically via Bluetooth. Additionally, the eLab system can publish Nanomix eLab COVID-19 Rapid Antigen Test results output as a QR code for privacy. 공시 • Aug 17
Boston Therapeutics, Inc. announced delayed 10-Q filing On 08/16/2021, Boston Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.